secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-09-03T12:47:46+00:00
Accession:  0001104659-26-104940
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie completes $10.9B cash acquisition of Apogee Therapeutics
---------------------------------------------------------------

- Apogee shareholders received $135.11/share cash; total equity value ~$10.9B.
- Adds zumilokibart (IL-13 mAb for atopic dermatitis) and APG273 (asthma candidate) to immunology pipeline.
- Deal dilutive to adjusted EPS by $0.14 in 2026 and ~$0.46 in 2027; accretion expected from 2032.
- AbbVie reaffirms FY2026 adjusted EPS guidance $13.87-$14.07 and Q3 guidance $3.84-$3.88.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/0001104659-26-104940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/tm2624674d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-104940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer